Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pliant Therapeutics (PLRX – Research Report) and Landos Biopharma (LABP – Research Report).
Pliant Therapeutics (PLRX)
TD Cowen analyst Ritu Baral maintained a Buy rating on Pliant Therapeutics today. The company’s shares closed last Friday at $13.89, close to its 52-week low of $13.04.
According to TipRanks.com, Baral is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pliant Therapeutics with a $47.64 average price target, representing a 205.0% upside. In a report released today, Piper Sandler also initiated coverage with a Buy rating on the stock with a $40.00 price target.
See today’s best-performing stocks on TipRanks >>
Landos Biopharma (LABP)
In a report released today, Sean Kim PhD from JonesTrading maintained a Hold rating on Landos Biopharma. The company’s shares closed last Friday at $3.60.
According to TipRanks.com, PhD ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Landos Biopharma has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PLRX:
- Pliant Therapeutics presents three posters on PLN-101095
- Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
- Pliant Therapeutics to highlight Phase 2a interim data on bexotegrast
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
- Pliant Therapeutics to participate in a conference call with JPMorgan
